Program Description
In this CME-certified program, Dr. Robert Motzer discusses how targeted therapies are changing the treatment of advanced renal cell carcinoma. The multi-targeted tyrosine kinase inhibitor (TKI) sunitinib and the mammalian target of rapamycin (mTOR) inhibitor temsirolimus have both demonstrated superiority over interferon-α in patients with metastatic RCC. Moreover, combination therapy with interferon-α and the antiangiogenic agent bevacizumab provides a progression-free survival benefit over interferon-α alone. For patients with metastatic RCC requiring second-line treatment, the multi-targeted TKI sorafenib has demonstrated a progression-free survival benefit over placebo. Ongoing studies are evaluating combinations of targeted agents to enhance their efficacy.

Target Audience
This activity will be designed for community- and hospital-based medical oncologists, hematologists, urologists, nephrologists, and allied healthcare providers who provide medical care and support to patients with renal cell carcinoma.

Learning Objectives
After completing this program, participants should be able to

	•	Describe the settings in which sunitinib, sorafenib, bevacizumab, and temsirolimus have demonstrated a clinical benefit in patients with metastatic RCC
	•	Improve outcomes in patients with metastatic RCC through the effective use of targeted therapies
	•	Explain to healthcare team the safety concerns with various targeted therapies

Faculty
Robert A. Figlin, MD (Activity Director)
Arthur and Rosalie Kaplan Chair in Oncology
Professor and Chair, Medical Oncology and Therapeutics Research
City of Hope National Medical Center and Beckman Research Institute
Associate Director for Clinical research
City of Hope Comprehensive Cancer Center
Duarte, California

Robert J. Motzer, MD
Attending Physician
Memorial Sloan-Kettering Cancer Center
Professor of Medicine
Weill Medical College of Cornell University
New York, New York

Accreditation
This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint sponsorship of the City of Hope and Alliance Medical Communications. The City of Hope is accredited by the ACCME to provide continuing medical education for physicians.

Designation of Credit
This activity is designated for .5 AMA Physicians’ Recognition Award™ credits. To receive your CME credits you are requested to review the material in full and take the post-test and evaluation. Your evaluation of the activity and comments will remain confidential.

Disclosure
City of Hope takes responsibility for the content, quality and scientific integrity of this continuing medical education (CME) activity. Prior to their participation in this City of Hope CME activity, all faculty/presenters have disclosed any real or apparent vested commercial interest(s) in both those companies whose products may be discussed during the course of the activity and in those companies acting as commercial supporters of the activity. City of Hope further requires that prior to the activity, faculty/presenters have disclosed their intention to discuss any off-label and/or investigational (not yet approved for any purpose) use of pharmaceuticals or medical devices. Written disclosure of faculty/presenters’ specific commercial relationships and/or intent to discuss off-label and/or investigational use of products is provided below.

Robert A. Figlin, MD (Activity Director)

Commercial Interest	Relationship
Amgen, GlaxoSmithKline plc; Keryx Biopharmaceuticals, Inc.; Pfizer Inc; Wyeth	Grant/Research Support
Keryx Biopharmaceuticals, Inc; Pfizer Inc; Wyeth	Consultant

Robert J. Motzer, MD

Commercial Interest	Relationship
Genentech, Inc.; Novartis AG; Pfizer Inc; Wyeth	Grant, Research Support
Bayer Healthcare AG; Onyx Pharmaceuticals, Inc.	Speakers’ Bureau

Dr. Motzer reported the following specific mention of off-label and/or investigational use of products within his presentation.

Product	Investigational and/or Off-Label Use
Bevacizumab	Renal cell carcinoma
IFN-α	Renal cell carcinoma

References

1.	Abrams TJ, Lee LB, Murray LJ, Pryer NK, Cherrington JM. SU11248 inhibits KIT and platelet-derived growth factor receptor beta in preclinical models of human small cell lung cancer. Mol Cancer Ther. 2003;2:471-478.
2.	Atkins MB, Hidalgo M, Stadler WM, et al. Randomized phase II study of multiple dose levels of CCI-779, a novel mammalian target of rapamycin kinase inhibitor, in patients with advanced refractory renal cell carcinoma. J Clin Oncol. 2004;22:909-918.
3.	Bracarda S, Porta C, Boni C, et al. Randomized prospective phase II trial of two schedules of sorafenib daily and interferon-α2a (IFN) in metastatic renal cell carcinoma (RAPSODY): GOIRC Study 0681. J Clin Oncol 2007 ASCO Annual Meeting Proceedings Part I. 2007;25(18S): Abstract 5100.
4.	Choueiri TK, Plantada A, Elson P, et al. Efficacy of sunitinib and sorafenib in metastatic papillary and chromophobe renal cell carcinoma. J Clin Oncol. 2008;26:127-131.
5.	Dutcher JP, Szczylik C, Tannir N, et al. Correlation of survival with tumor histology, age, and prognostic risk group for previously untreated patients with advanced renal cell carcinoma (adv RCC) receiving temsirolimus (TEMSR) or interferon-alpha (IFN). J Clin Oncol 2007 ASCO Annual Meeting Proceedings Part I. 2007;25(18S): Abstract 5033.
6.	Escudier B, Eisen T, Stadler WM. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med. 2007;356:125-134.
7.	Escudier B, Pluzanska A, Koralewski P, et al. Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial. Lancet. 2007;370:2103-2111.
8.	Figlin RA, T. E. Hutson, P. Tomczak, et al. Overall survival with sunitinib versus interferon (IFN)-alfa as first-line treatment of metastatic renal cell carcinoma (mRCC). J Clin Oncol. 2008;26(May 20 suppl): Abstract 5024.
9.	Gollob JA, Rathmell WK, Richmond TM, et al. Phase II trial of sorafenib plus interferon alfa-2b as first- or second-line therapy in patients with metastatic renal cell cancer. J Clin Oncol. 2007;25:3288-3295.
10.	Gore ME, Porta C, Oudard S, et al. Sunitinib in metastatic renal cell carcinoma (mRCC): preliminary assessment of toxicity in an expanded access trial with subpopulation analysis. J Clin Oncol 2007 ASCO Annual Meeting Proceedings Part I. 2007;25(18S): Abstract 5010.
11.	Hudes G, Carducci M, Tomczak P, et al. Temsirolimus, interferon, or both for advanced renal-cell carcinoma. N Engl J Med. 2007;356:2271-2281.
12.	Jonasch E, Corn P, Ashe RG, Do K, Tannir NM. Randomized phase II study of sorafenib with or without low-dose IFN in patients with metastatic renal cell carcinoma. J Clin Oncol 2007 ASCO Annual Meeting Proceedings Part I. 2007;25(18S): Abstract 5104.
13.	Motzer RJ, Hutson TE, Tomczak P, et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med. 2007;356:115-124.
14.	Motzer RJ, Michaelson MD, Redman BG, et al. Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma. J Clin Oncol. 2006;24(1):16-24.
15.	National Comprehensive Cancer Network. "Kidney Cancer." NCCN Clinical Practice Guidelines in Oncology 2007;v.1.2008.
16.	Nexavar package insert. Bayer HealthCare Pharmaceuticals Inc.; 2008.
17.	Patel PH, Chadalavada RS, Ishill NM, et al. Hypoxia-inducible factor (HIF) 1α and 2α levels in cell lines and human tumor predicts response to sunitinib in renal cell carcinoma (RCC). J Clin Oncol. 2008;26 (May 20 suppl; abstr 5008).
18.	Presta LG, Chen H, O’Connor SJ, et al. Humanization of an anti-vascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders. Cancer Res. 1997;57:4593-4599.
19.	Ratain MJ, Eisen T, Stadler WM, et al. Phase II placebo-controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma. J Clin Oncol. 2006;24:2505-2512.
20.	Rini BI, Halabi S, Rosenberg JE, et al. CALGB 90206: A phase III trial of bevacizumab plus interferon-alpha versus interferon-alpha monotherapy in metastatic renal cell carcinoma. 2008 ASCO Genitourinary Cancers Symposium. Abstract 350.
21.	Ryan CW, Goldman BH, Lara PN Jr, et al. Sorafenib with interferon alfa-2b as first-line treatment of advanced renal carcinoma: a phase II study of the Southwest Oncology Group. J Clin Oncol. 2007;25:3296-3301.
22.	Search for Clinical Trials. A U.S. National Institutes of Health website. Available at: http://www.clinicaltrials.gov. Accessed January 16, 2008 and March 21, 2008.
23.	Seeliger H, Guba M, Kleespies A, et al. Role of mTOR in solid tumor systems: a therapeutical target against primary tumor growth, metastases, and angiogenesis. Cancer Metastasis Rev. 2007;26(3-4):611-621.
24.	Sutent package insert. Pfizer Labs; 2008.
25.	Tamaskar I, Garcia JA, Elson P, et al. Antitumor effects of sunitinib or sorafenib in patients with metastatic renal cell carcinoma who received prior antiangiogenic therapy. J Urol. 2008;179:81-86.
26.	Wilhelm SM, Carter C, Tang L, et al. BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the Raf/Mek/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res. 2004;64:7099-7109.
27.	Yang JC, Haworth L, Sherry RM, et al. A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med. 2003;349:427-434.